Background: Patients who present with symptoms mimicking ischaemic stroke (IS), but have a different diagnosis, are known as stroke mimics (SM). The necessity for rapid administration of intravenous thrombolysis in patients with acute IS may lead to treatment of patients with conditions mimicking stroke. A variable proportion of patients with SM (1.4–14%) are currently treated with intravenous tissue plasminogen activator therapy (IV-tPA). The outcome of these patients is generally favourable and complications are rather infrequent. We aimed to determine the frequency, clinical features and prognosis of SM patients treated with IV-tPA in an experienced stroke centre. Methods: A prospective registry was assembled with patients treated with IV-tPA at our stroke unit from January 2004 to December 2011. We recorded age, gender, baseline National Institutes of Health Stroke Scale (NIHSS) score, treatment delay, vascular risk factors, clinical syndrome and aetiology. We retrospectively analysed the clinical characteristics of SM, safety (symptomatic intracranial haemorrhage and mortality) and outcome measures (modified Rankin Scale at 3 months, mRS) and compared them with IS patients. Results: 621 patients were treated with IV-tPA during the study period, 606 (97.5%) were IS and 15 (2.4%) were SM. The aetiology of SM was somatoform disorders (5), headache and neurological deficits with cerebrospinal fluid lymphocytosis (HaNDL) syndrome (3), herpetic encephalitis (2), glial tumours (2), and migraine with aura, focal seizure and cortical vein thrombosis in single cases. SM were younger (72 ± 14 vs. 53.7 ± 16 years, p < 0.05), had a lower baseline deficit [NIHSS 13 (9–18) vs. 8 (5–10), p < 0.05], fewer vascular risk factors, and left hemisphere symptoms were predominant (80 vs. 52.4%, p < 0.05). Global aphasia without hemiparesis (GAWH) was the presenting symptom in 8 (54%) SM and 44 (7%) IS (p < 0.05). Multimodal computed tomography was performed in 3 SM patients and showed perfusion deficits in 2 of them. No intracranial haemorrhage or disability (functional outcome at 3 months, mRS >2) was recorded in any SM patient. Conclusions: The use of intravenous thrombolysis appears to be safe in our SM patients, and prognosis is universally favourable. Somatoform disorder and HaNDL syndrome were prominent causes, and GAWH the most common presentation. The safety of thrombolysis in SM suggests that delaying or withholding treatment may be inappropriate: the benefit of thrombolysis in case of IS may outweigh the risks of treating an SM. Further studies may assess the future role of multimodal computed tomography in the differential diagnosis between IS and SM.

Keywords:
Stroke mimics, Stroke and thrombolysis, Stroke diagnostics, Stroke therapy, Thrombolytic treatment, Ischaemic stroke
1.
Hemmen TM, Meyer BC, McClean TL, Lyden PD: Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center. J Stroke Cerebrovasc Dis 2008;17:23–25.
2.
Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM: Distinguishing between stroke and mimic at the bedside: the Brain Attack Study. Stroke 2006;37:769–775.
3.
Ay H, Buonanno FS, Rordorf G, Schaefer PW, Schwamm LH, Wu O, Gonzalez RG, Yamada K, Sorensen GA, Koroshetz WJ: Normal diffusion-weighted MRI during stroke-like deficits. Neurology 1999;52:1784–1792.
4.
Scott PA, Silbergleit R: Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. Ann Emerg Med 2003;42:611–618.
5.
Artto V, Putaala J, Strbian D, Meretoja A, Piironen K, Liebkind R, Silvennoinen H, Atula S, Häppölä O: Stroke mimics and intravenous thrombolysis. Ann Emerg Med 2012;59:27–32.
6.
Winkler DT, Fluri F, Fuhr P, Wetzel SG, Lyrer PA, Ruegg S, Engelter ST: Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke 2009;40:1522–1525.
7.
Chernyshev OY, Martin-Schild S, Albright KC, Barreto A, Misra V, Acosta I, Grotta JC, Savitz SI: Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010;74:1340–1345.
8.
Chen Y, Bogosavljevic V, Leys D, Jovanovic D, Beslac-Bumbasirevic L, Lucas C: Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile. Eur J Neurol 2011;18:1246–1250.
9.
Tsivgoulis G, Alexandrov AV, Chang J, Sharma VK, Hoover SL, Lao AY, Liu W, Stamboulis E, Alexandrov AW, Malkoff MD, Frey JL: Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke 2011;42:1771–1774.
10.
Amort M, Fluri F, Schäfer J, Weisskopf F, Katan M, Burow A, Bucher HC, Bonati LH, Lyrer PA, Engelter ST: Transient ischemic attack versus transient ischemic attack mimics: frequency, clinical characteristics and outcome. Cerebrovasc Dis 2011;32:57–64.
11.
Förster A, Griebe M, Wolf ME, Szabo K, Hennerici MG, Kern R: How to identify stroke mimics in patients eligible to intravenous thrombolysis? J Neurol DOI: 10.1007/s00415-011-6354-9.
12.
Grimm SA, DeAngelis LM: Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology 2007;69:936.
13.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental, ed 4, rev. Washington, American Psychiatric Association, 2000.
14.
WHO: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, World Health Organisation, 1992.
15.
Hacke W, Kaste M, Bluhmki E, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
16.
European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
17.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
18.
Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275–282.
19.
Headache Classification Subcomittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:9–160.
20.
Segura T, Hernández-Fernández F, Sánchez-Ayaso P, Lozano E, Abad L: Usefulness of multimodal MRI imaging in the differential diagnosis of HaNDL and acute ischemic stroke. BMC Neurol 2010;10:120.
21.
Gómez-Aranda F, Cañadillas F, Martí-Massó JF, Díez-Tejedor E, Serrano PJ, Leira R, Gracia M, Pascual J: Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases. Brain 1997;120:1105–1113.
22.
Masjuan J, Buisan J, Frutos T, Quereda C, Alvarez-Cermeño JC: The not so benign syndrome of transient headache with neurologic deficits and CSF lymphocytosis. Neurology 1998;51;313–314.
23.
Vallen AE, Desestret V, Tahon F, Cho T, Nighoghossian N: Acute perfusion MRI imaging in a HaNDL-like syndrome. Cerebrovasc Dis 2010;29:98–100.
24.
Marco de Lucas E, González Mandly A, Gutiérrez A, Sánchez E, Arnáiz J, Piedra T, Rodríguez E, Díez C: Computed tomography perfusion usefulness in early imaging diagnosis of herpes simplex virus encephalitis. Acta Radiol 2006;47:878–881.
25.
Agarwal S, Jones PS, Alawneh JA, Antoun NM, Barry PJ, Carrera E, Cotter PE, O’Brien EW, Salih I, Scoffings DJ, Baron JC, Warburton EA: Does perfusion computed tomography facilitate clinical decision making for thrombolysis in unselected acute patients with suspected ischaemic stroke? Cerebrovasc Dis 2011;32:227–233.
26.
Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, Welsh P, Green A, Andrews M, Graham C, Sandercock P: Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis 2011;32:141–147.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.